NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
07/29/2026
Back to search
Official data from USPTO
OPTICYTE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
14
Latest update
07/29/2026
Trademark type
Word
Nice classes
5
Filing date
06/29/2020
Registration date
01/26/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/29/2026
Last transaction
07/29/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
08/18/2017
First use in commerce
05/05/2020
Drawing code
4
Owner type
03
Owner location
Durham, NC, US
Examiner
BROWN, BARBARA TROFFKIN
Current location
Historical data usage
Holders and representatives
Holders
MERAKRIS THERAPEUTICS, INC.
Merakris Therapeutics, LLC
Representatives
Karen Hahn
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Human biological amniotic membrane or other postpartum tissues intended for subsequent implantation; human biological amniotic tissue or other postpartum tissues that may include amniotic membraneamniotic fluidumbilical cordplacentaintended for medical use for the treatment or prevention of ophthalmic diseasesthe treatment of woundsulcersburnsscars and surgical incisions involving the eye; human biological tissueplacental-derived tissue for use in biological tissue grafts for use in surgery and wound repair involving the eye; topical treatment in the nature of an allograft for medical use for the treatment of woundsulcersburnsscars and surgical incisions involving the eyethe treatment or prevention of ophthalmic diseases; topical treatment made from amniotic material in the nature of a wound dressing for medical use for the treatment of woundsulcersburnsscars and surgical incisions involving the eye; topical treatment made from amniotic material in the nature of an allograft for medical use for the treatment of woundsulcersburnsscars and surgical incisions involving the eye; wound treatment in the nature of amniotic material prepared in sheet forms or viscous forms
Publications
History of USPTO decisions and trademark events.
14 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
07/29/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/27/2026
E815
TEAS SECTION 8 & 15 RECEIVED
04/24/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/26/2026
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
01/25/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/26/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/10/2020
PUBO
PUBLISHED FOR OPPOSITION
11/10/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/21/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/30/2020
DOCK
ASSIGNED TO EXAMINER
09/30/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/25/2020
NWAP
NEW APPLICATION ENTERED
07/02/2020
Continuous trademark protection
Get notified about every new filing that threatens OPTICYTE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.